Product Images Midazolam

This text provides dosing information for intramuscular midazolam to be used for sedation/anxiolysis in pediatric patients. Higher doses can result in prolonged sedation, but doses ranging from 0.1 to 0.15 mg/kg are usually effective without prolonging emergence from anesthesia or general anesthesia. Midazolam can be used to sedate pediatric patients to facilitate the insertion of an intravenous catheter for the administration of additional medication. The total intramuscular dose usually does not exceed 10 mg. If midazolam is given with an opioid, the initial dose of each must be reduced.*

This is a medical document that provides guidelines for dosing of midazolam for pediatric patients undergoing sedation or anesthesia prior to a medical procedure. The guidelines suggest beginning with small doses and increasing gradually until the appropriate level of sedation is achieved, and caution should be taken when administering to patients under six months of age. It also advises that dosing may need to be adjusted depending on factors such as patient response, the type and duration of the procedure, and the use of concomitant medications.*

This appears to be a medical document discussing the use and dosage of midazolam for pediatric patients, both neonatal and non-neonatal, via intravenous infusion. It provides specific information on suggested loading doses and continuous infusion rates, as well as potential side effects and precautions to consider for patients with respiratory depression or requiring intubation. For neonatal patients, there is also discussion of administration rates and monitoring for adverse effects.*

This is a unit of sale for a medication with the National Drug Code (NDC) 0409-2587-05. The concentration of the medication is 10 mg/10 mL (1 mg/mL) and the unit of sale is a box of 10.*

This is a product of sale with two different options available. The first option has a concentration of 25mg/5mL (5mg/mL) and comes in a box of 10, while the second option has a concentration of 50mg/10mL (5mg/mL) and also comes in a box of 10. Both options have an NDC (National Drug Code) of 0409-2596-03 and 0409-2596-05 respectively.*

This text provides information on the recommended dose of midazolam, a sedative used for preoperative purposes. The recommended IM dose is between 0.07 to 0.08 mg/kg for good risk adult patients under the age of 60, with dosage varying for other patient categories such as those with pulmonary disease, older than 60 years, or those taking narcotics, etc. Midazolam is injected deep into a large muscle mass, with its effects lasting up to 60 minutes after onset in 15 minutes. It can be administered alongside other medications.*

Midazolam is a medication used for sedation, anxiolysis, and amnesia during medical procedures. For optimal results, narcotic premedication is recommended, and the use of an appropriate topical anesthetic is advised for peroral procedures. Midazolam dosage must be individualized and titrated, and it should be slowly administered and evaluated for its effect. Response to the medication may vary depending on age, physical status, concomitant medications, and other factors. The medication has certain warnings concerning cardiac/respiratory arrest, airway obstruction, and hypoventilation.*

Midazolam is a sedative drug used for procedures to facilitate slow injection. It comes in two formulations, 1mg/mL and 5mg/mL, both of which may be diluted with 0.9% sodium chloride or 5% dextrose in water. The dosage and titration of midazolam should be carefully adjusted according to the patient's age, health status, and response to the drug. In healthy adults below the age of 60, the initiation dosage should be titrated slowly to the desired effect, and not more than 2.5 mg should be given over a period of at least 2 minutes. For patients age 60 or older, and those who are debilitated or chronically ill, the increments should be smaller, and the rate of injection slower. Additional doses to maintain the desired level of sedation may be given by slow titration, only after a thorough clinical evaluation indicates the need for additional sedation.*

This text is a guideline for the administration of midazolam for induction of general anesthesia. It provides information on how to adjust the dosage according to the age and clinical status of the patient, with and without premedication. The response to the drug may vary among individuals, and in the absence of premedication, an initial dose of 0.3 to 0.35 mg/kg is typical for most adults. For older or debilitated patients, a lower initial dose is recommended. Narcotic and sedative premedications may also be used, with specific recommended dosages and administration times.*

The text describes the use of injectable midazolam in anesthesia for surgical procedures, as a component of balanced anesthesia. A recommended dose is given for both loading and maintenance infusion rates, to achieve adequate sedation while taking into account patient's age, clinical status, and current medications. The infusion rate should be adjusted regularly to maintain the desired level of sedation, and the minimum effective rate should be found in order to avoid accumulation and ensure a quick recovery. An opioid analgesic can also be administered to reduce the minimum effective midazolam infusion rate.*

Pediatric patients require higher dosages of midazolam on a mg/kg basis compared to adults. Dosages vary depending on the patient's age, with younger patients generally requiring higher dosages and closer monitoring. Obese pediatric patients should have their dosage calculated based on ideal body weight. When combined with opioids or other sedatives, the potential for respiratory depression, airway obstruction, or hypoventilation increases. Healthcare practitioners using this medication on pediatric patients should follow appropriate professional guidelines for pediatric sedation.*

The given text describes the Observer's Assessment of Alertness/Sedation (OAA/S) and the responses corresponding to different levels of alertness. The responses are categorized into different levels based on the response to various stimuli such as name-spoken, prodding, and shaking. The highest level of alertness corresponds to a clear and prompt response, while the lowest level represents no response to mild prodding or shaking.*

This is a description of a medicine called Midazolam, with a concentration of 25mg/ml. It can be administered through injection and it's recommended for intravenous use with regular frequency. It comes in a packaging identified as B4G4-5915-05 and LOT JOOOCKKKX, with specific expiration dates that must be provided in the manufacturer's insert. It was packaged by Henry Schein, Inc. for use in a controlled room temperature. The address of the package recipient is Bastian, VA 24314.*